Politician trade (House)

Bio-Techne (TECH): Rep. April McClain Delaney (MD06) disclosed a partial sale $1K–$15K

Rep. April McClain Delaney (MD06) disclosed a partial sale of Bio-Techne in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
14 days
Disclosure lag
Traded
Feb 24, 2026
Disclosed
Mar 10, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 2, 2025CongressDisclosed purchase of TECH — reported range $1,001 - $15,000
  2. Dec 5, 2025CongressDisclosed purchase of TECH — reported range $1,001 - $15,000
  3. Jan 28, 2026CongressDisclosed partial sale of TECH — reported range $1,001 - $15,000
  4. Feb 4, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  5. Feb 9, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On February 11, 2026, Bio-Techne Corporation (the “Company”) announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition.”
  6. Feb 17, 2026InsiderDirector sold ~$117K of TECH shares in the open market
  7. Feb 24, 2026 · this disclosureCongressDisclosed partial sale of TECH — reported range $1,001 - $15,000

What came next

  1. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  2. Mar 26, 2026CongressDisclosed partial sale of TECH — reported range $1,001 - $15,000
  3. Apr 8, 2026CongressDisclosed sale of TECH — reported range $1,001 - $15,000
  4. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.4%
  5. May 6, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  6. May 6, 20265% stakeFMR LLC reported a passive stake (13G) of 5.0%
  7. May 8, 2026InsiderDirector sold ~$320K of TECH shares in the open market
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Bio-Techne

For Bio-Techne, OQRO holds 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TECH page.

Other recent filings by Rep. April McClain Delaney (MD06)

The full history of Rep. April McClain Delaney (MD06) is on the profile page.

How this filing works

Explore the data

Common questions

Which member of Congress traded Bio-Techne (TECH) stock, and how much?

Rep. April McClain Delaney (MD06) disclosed a partial sale of Bio-Techne in the $1K–$15K range. Reported range, not an exact amount, Dependent child account.

When did it happen, and when was it made public?

Traded: Feb 24, 2026. Disclosed: Mar 10, 2026. That is 14 days between the two dates.

Why is the amount a range and not an exact figure?

Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.

Where does this information come from?

From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Bio-Techne recently?

For Bio-Techne, OQRO holds 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the TECH page.

Does this mean TECH stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Bio-Techne

Everything OQRO holds on this company is on its TECH page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data